

# Contents

<b>Abstract</b> .....	<b>6</b>
<b>1. Introduction</b> .....	<b>7</b>
1.1 Smoking behavior and nicotine.....	7
1.2 The nicotinic acetylcholine receptor (nAChR).....	10
1.3 A link between smoking and cognition?.....	12
1.3.1 The self-medication hypothesis in schizophrenia.....	12
1.3.2 The self-medication hypothesis in ADHD.....	17
1.3.3 Procognitive effects of nicotine in Parkinson’s and Alzheimer’s diseases.....	19
1.3.4 Self-medication in a sub-population of “normal” smokers.....	20
1.4 Genetic evidence for the role of cholinergic neurotransmission in cognition.....	22
1.4.1 Polymorphisms in the <i>CHRNA4</i> gene.....	23
1.4.2 Polymorphisms in the <i>CHRNA3</i> gene.....	25
1.4.3 Polymorphisms in the <i>CHRNA7</i> gene.....	26
1.5 Clinical trials searching for nicotinic agonists to treat attentional impairments.....	29
1.6 Cholinergic modulation of executive control.....	33
1.7 The antisaccade task as a measure of executive control.....	35
1.7.1 The antisaccade task as a useful tool for investigating cholinergic effects.....	40
1.8 Hypotheses and aims of the present studies.....	41
<b>2. Empirical Studies</b> .....	<b>43</b>
2.1 Study 1: Genetic study: <i>CHRFAM7A</i> copy number and 2bp deletion polymorphisms and antisaccade performance (Petrovsky et al., 2009).....	43
2.1.1 Abstract.....	43
2.1.2 Keywords.....	43
2.1.3 Introduction.....	44
2.1.4 Method.....	47
2.1.5 Results.....	49
2.1.6 Discussion.....	54
2.2 Study 2: Nicotine study: Nicotine differentially modulates antisaccade performance in healthy male non-smoking volunteers stratified for low and high accuracy (Petrovsky et al., in press).....	57
2.2.1 Abstract.....	57
2.2.2 Keywords.....	58
2.2.3 Introduction.....	58
2.2.4 Methods and materials.....	61
2.2.5 Results.....	70
2.2.6 Discussion.....	78
<b>3. Discussion</b> .....	<b>85</b>
3.1 Molecular genetic studies of antisaccade performance and suggestions for future pharmacogenetic investigations.....	85
3.1.1 Cholinergic polymorphisms.....	86
3.1.2 Dopaminergic polymorphisms.....	88
3.1.3 Serotonergic polymorphisms.....	93
3.1.4 Polymorphisms in risk genes for schizophrenia.....	97

3.2 Cholinergic modulation of antisaccade performance – mediated by the effects of dopamine? .....	99
3.3 Cognitive effects of nicotine: Do nicotinic acetylcholine receptors act as moderator variables in complex cortical networks? .....	105
3.4 Methodological issues, strengths and limitations of the present studies .....	109
3.5 Conclusions .....	113
<b>German Summary (Deutsche Zusammenfassung).....</b>	<b>116</b>
<b>Abbreviations.....</b>	<b>134</b>
<b>Glossary.....</b>	<b>139</b>
<b>List of Tables.....</b>	<b>144</b>
<b>List of Figures .....</b>	<b>145</b>
<b>References .....</b>	<b>146</b>